Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth. by Cantelmo, Anna Rita




Scuola di Dottorato in Scienze Biologiche e Mediche 








Cell delivery of Met docking site peptides 



















Academic Year 2009-2010 
 
List of abbreviations 
 
17-AAG  17-allylamino-17-demethoxygeldanamycin 
8-Cl-Ado  8-clhoro-adenosine 
Antp   Antennapedia homeodomain 
CML   Chronic myelogenous leukaemia 
CPPs   Cell-penetrating peptides 
ECM    Extracellular Matrix  
ECs    Endothelial Cells 
EGF   Epidermal Growth Factor 
EGFR    Epidermal Growth Factor Receptor 
EPCs    Endothelial Precursors Cells  
FAM   5-(and-6)-carboxyfluorescein 
FBS   Fetal bovine serum 
FDA   Food and Drug Administration 
FGFs    Fibroblast Growth Factors 
HGF    Hepatocyte Growth Factor  
HIF    Hypoxia-inducible Transcription Factor 
HIV   Human Immunodeficiency Virus 
HUVEC   Human Umbilical Vein Endothelial Cells 
Met    Mesenchimal Epithelial Transition, HGF receptor 
MRS   Met related sequence 
MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5 
diphenyltetrazolium bromide] 
NSCLC  Non-small-cell lung cancer 
OS   Overall survival 
PBS   Phosphate- buffered saline 
PDGFRs  Platelet-derived Growth Factor Receptors 
PDGFs  Platelet-derived Growth Factors 
PEI   Polyethyleneimine 
PFS   Progression free survival 
PlGF   Placental Growth Factor 
PTDs   Protein transduction domains 
RCC   Renal cell carcinoma 
RTKIs   Tyrosine kinase inhibitors 
SFM   Serum free medium 
SH2   Src homology-2 
SMCs    Smooth Muscular Cells  
TGF-β   Trasforming Growth Factor-β 
TNF-α   Tumor necrosis factor−α 
VEGFRs  Vascular Endothelial Growth Factor Receptors 




1. Introduction       pag.1 
1.1.Angiogenesis        pag.1 
1.1.1. Pathological angiogenesis    pag.3 
1.1.2. Tumor angiogenesis and the angiogenic switch  pag.5 
1.1.3. Angiogenic growth factors and their receptors pag.9 
1.1.4. Modern approach in angiogenesis inhibition  pag.12 
1.2. Hepatocyte growth factor and its receptor Met  pag.16 
1.2.1. Met and the invasive growth: from development to 
metastasis       pag.19 
1.2.2. Met receptor as a therapeutic anticancer target pag.21 
 
2. Aim of the Project      pag.25 
 
3. Materials and Methods      pag.28 
3.1. Reagents       pag.28 
3.2. Cell cultures       pag.29 
3.3. Cytofluorimetric analysis     pag.29 
3.4. Immunofluorescence analysis    pag.30 
3.5. In vitro cell viability      pag.30 
3.6. Migration assay      pag.31 
3.7. Invasion assay      pag.32 
3.8. Morphogenesis assay     pag.32 
3.9. Western blotting      pag.33 
3.10. In vivo matrigel sponge assay   pag.34 
3.11. In vivo xenograft tumor growth   pag.34 
3.12. Histological analysis     pag.35 
3.13. Statistical analyses     pag.36 
 
4. Results        pag.37 
4.1. Cell internalization of the Met docking site peptide pag.37 
4.2. Met docking site peptides inhibit HUVEC proliferation pag.38 
4.3. Met docking site peptides do not exert toxicity or    
induce apoptosis in endothelial cells    pag.40 
4.4. Met docking site peptide specifically inhibits    
 HGF-dependent HUVEC migration and invasion  pag.42 
4.5. The Met docking site peptide inhibits  
endothelial morphogenesis in vitro    pag.43 
4.6. The Met docking site peptide inhibits  
HGF-dependent downstream signalling   pag.45 
 
4.7. Met docking site peptide inhibits in vivo angiogenesis pag.46 
4.8. Met docking site peptide inhibits the growth and  
vascularization of Kaposi’s sarcomas in nude mice  pag.48
      
5. Discussion and Conclusion     pag.52 
 




Angiogenesis is a very complex biological process that drives the 
formation of new blood vessels starting from pre-existing one. In 
adulthood, it occurs both in physiological and pathological processes. 
Pathological angiogenesis is involved in several diseases, including 
cancer. In the last decade, the concept of anti-angiogenic therapy has 
been developed as a strategy to treat cancer inducing the inhibition of 
new vessels that provide sustenance to the tumor. Recently, Met receptor 
and its ligand HGF (Hepatocyte Growth Factor) has been proposed as 
target for the anti-angiogenic therapy.  
HGF and its receptor Met are responsible for a wide variety of cellular 
responses, both physiologically during embryo development and tissue 
homeostasis, and pathologically, particularly during tumor growth and 
dissemination. In cancer, Met can act as an oncogene on tumor cells, as 
well as a pro-angiogenic factor activating endothelial cells and inducing 
new vessel formation. Molecules interfering with Met activity could be 
valuable agents for anti-cancer treatment simultaneously inhibiting 
oncogenesis and angiogenesis. 
The aim of this study has been the identification of peptides able to 
interfere with HGF-induced angiogenesis.  
We synthesized three different peptides containing the Met docking site 
fused to the internalization sequences of Antennapedia homeodomain or 
of Tat transactivation domain which were used to deliver peptides into 
living cells. 
In vitro we treated human endothelial cells with peptides and we 
quantified proliferation. We then evaluated the ability of peptides to 
interfere with HGF-induced migration, invasion and morphogenesis of 
 
endothelial cells. By western blotting analysis we investigated whether 
these peptides affect Met activation and downstream signalling. In vivo 
we performed matrigel sponge assay and Kaposi’s sarcoma xenograft to 
test the peptides efficacy on angiogenesis and tumor growth.  
We observed that in endothelial cells internalized peptides inhibited 
ligand-dependent cell proliferation, motility, invasiveness and 
morphogenesis in vitro, to an even greater extent and with much less 
toxicity than the Met inhibitor PHA-665752, which correlated with 
interference of HGF-dependent downstream signalling, as shown by 
reduction in ERK1/2 activation (Cantelmo et al.). In vivo, the peptides 
inhibited HGF-induced angiogenesis in the matrigel sponge assay and 
impaired xenograft tumor growth and vascularization in Kaposi’s 
sarcoma (Cantelmo et al.).  
These data show that interference with the Met receptor intracellular 
sequence impairs HGF-induced angiogenesis, suggesting the use of anti-
docking site compounds as a therapeutic strategy to counteract 





Blood vessels are essential for development and reorganization of tissues 
in the organisms. They transport gases, liquids, nutrients, signalling 
molecules and circulating cells between tissues and organs, removing 
the catabolic products. This task is carried out by the blood vessels and 
the lymphatic vessels, which internal walls are formed by endothelial 
cells (ECs). Both endothelial networks are essential for homeostasis in 
the healthy organism (Rocha and Adams, 2009). The vascular system is 
generated by two different processes: vasculogenesis and angiogenesis 
(Figure 1). Vasculogenesis refers to the formation of blood vessels by 
endothelial cell precursors (EPCs), the angioblasts, deriving from the 
hemangioblasts (Risau and Flamme, 1995). The juvenile vascular 
system then evolves from the primary capillary plexus by subsequent 
pruning and reorganization of endothelial cells in a process called 
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Figure 1: Origin of endothelial cells and assembly of the vasculature 
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Recent studies suggest that the incorporation of bone marrow-derived 
endothelial progenitor cells (EPCs) in the growing vessels complements 
the sprouting of resident endothelial cells (Asahara et al., 1997; De 
Palma et al., 2003; Rafii et al., 2002). 
During development hemangioblasts, a mesodermal common precursor 
of endothelial and hematopoietic stem cells (HSCs), aggregate to form 
the blood islands. These structures proliferate and migrate to form a 
network of tubular structures characterized by two layers: the internal 
layer becomes the endothelial coating of the nascent vessels, while the 
external layers differentiate to smooth muscular cells (SMCs) or 
pericytes. Between them there is the basal lamina rich in collagen. The 
fusion of blood islands forms primitive vascular plexus, in which the 
venous and arterial systems are already distinct (Risau and Flamme, 
1995). The vascular plexus is immature and fragile and it needs the 
angiogenic and arteriogenic process to be stabilized.  
Angiogenesis is the formation of new blood vessels starting from pre-
existing ones. It is a complex process divided in different phases. The 
first step consists in the increase of vascular permeability of pre-existing 
vessels. This process requires the extracellular matrix (ECM) breakdown 
by proteinases, including plasminogen activator, metalloproteinases, 
heparinases, tryptates and cathepsyns (Alexander and Elrod, 2002). The 
ECs can migrate to the sites where angiogenesis is required, where they 
proliferate and differentiate. In the second phase there is a block of ECs 
migration and proliferation processes occurred to form a new network of 
vessels. Hypoxia is an important stimulus for expansion of the vascular 
bed, triggering vessel growth by signalling through hypoxia-inducible 
transcription factors (HIF) (Safran and Kaelin, 2003). HIFs up-regulate 
many angiogenic genes, such as VEGFs (Vascular Endothelial Growth 
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Factors), angiopoietins, FGFs (Fibroblast Growth Factors) and related 
receptors (Pugh and Ratcliffe, 2003). These stimuli regulate the 
formation of a mature vessel network, that is stabilized by the addiction 
of several layers of SMCs (Carmeliet, 2003). 
Vascular endothelium is versatile, has multiple functions and activities 
of synthesis and metabolism. It is dynamic and actively takes part in the 
interactions between blood flow and tissue. In fact, it acts as a 
semipermeable membrane that regulates molecular exchanges, 
modulates vascular tone and blood flow, and regulates the immune 
response by controlling, for example, leucocyte adhesion. 
 
1.1.1 Pathological angiogenesis 
Judah Folkman described several years ago the association between 
growing solid malignant tumors and new vessel growth, proposing that 
anti-angiogenesis might represent a therapy for solid tumors (Folkman, 
1971). Since then, much effort has been done in the elucidation of the 
mechanisms of angiogenesis. 
Pathological angiogenesis is characterized by an excessive or an 
insufficient vessels formation. Deregulated vessels growth contributes to 
the pathogenesis of many disorders, some quite unexpected. Indeed, a 
long list of disorders is characterized or caused by excessive 
angiogenesis. Historically the best known are cancer, psoriasis, arthritis 
and blindness, but many additional common disorders such as obesity, 
asthma, atherosclerosis and infections disease are included and the list is 
still growing (Table 1). In addition, insufficient vessel growth and 
abnormal vessel regression not only causes heart and brain ischemia, but 
can also lead to neurodegeneration, hypertension, pre-eclampsia, 
respiratory distress, osteoporosis and other disorders (Table 2). However 
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the vast importance of angiogenesis as possible therapeutic target has 
been the driving force for the elucidation of its molecular mechanisms. 
 
Organ Diseases in mice or humans 
 Numerous 
organs 
Cancer, infectious diseases, autoimmune disorders 
Blood vessels Vascular malformation, cavernous hemangioma, 




Skin Psoriasis, warts, allergic dermatitis, scar keloids, pyogenic 
granulomas, Kaposi sarcoma in AIDS patients 
Eye Persistent hyperplastic vitreous syndrome, diabetic 
retinopathy, retinopathy of prematurity, choroidal 
neovascularization 
Lung Primary pulmonary hypertension, asthma, nasal polyps 




Endometriosis, uterine bleeding, ovarian cysts, ovarian 
hyperstimulation 
Bone, joints Arthritis, synovitis, osteomyelitis, osteophyte formation 
  
Modified from Nature Medicine  9(6):653-660 (June 2003) 
 













Organ Disease in mice or humans 
Nervous system Alzheimer  disease, amyotrophic lateral sclerosis, diabetic 
neuropathy, stroke 
Blood vessels Atherosclerosis, hypertension, diabetes 
Gastrointestinal  
system 
Gastric or oral ulcerations, Chron disease 





Lung Neonatal respiratory distress, pulmonary fibrosis, 
emphisema 
Kidney Nephropathy 
Bone Osteoporosis, impaired bone fracture healing 
 
Modified from Nature Medicine  9(6):653-660 (June 2003) 
 
Table 2: Diseases characterized or caused by insufficient angiogenesis or 
vessel regression 
 
Application of specific compounds that may inhibit or induce the 
creation of new blood vessels in the body may help to combat such 
diseases. The last two decades have seen an explosive progress in our 
understanding of the angiogenesis pathways underlying growth and 
differentiation of blood vessels. On the basis of these results several 
anti-angiogenic therapies have been developed with the aim to modulate 
pathological angiogenesis (Carmeliet, 2003). 
 
1.1.2 Tumor angiogenesis and the angiogenic switch  
The vasculature is usually quiescent in the adult life and occurs only in 
few tissues including female reproductive organs, organs that are 
undergoing physiological growth  or injured tissue (Hanahan and 
Folkman, 1996). The formation of a tumor-associated vasculature, a 
process referred to as tumor angiogenesis, is essential for cancer 
progression, as it permits tumor expansion, favours local invasion and 
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provides a route for metastatic dissemination (Folkman, 1972). Studies 
suggest that if the vascularisation of tumors can be blocked, the tumor 
mass will be limited in size. Further, the acquisition of the angiogenic 
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Figure 2: The classical angiogenic switch 
 
The angiogenic switch can occur at different stages of the tumor 
progression pathway and it depends on the nature of tumor and its 
microenvironment (Figure 2). The switch begins with perivascular 
detachment and vessel dilatation, followed by angiogenic sprouting, new 
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vessel formation and maturation, and the recruitment of perivascular 
cells (Bergers and Benjamin, 2003). 
Tumor vessels display a different structure, easy to discriminate from the 
normal vessels (Pasqualini et al., 2002). Vascular structures are irregular 
and disorganized: they have an irregular diameter, casual branches, are 
more permeable, hemorrhagic; the blood flow is altered and may show 
stasis or invert flow direction. An aberrant architecture leads to an 
altered functionality (Bergers and Benjamin, 2003). Vessel walls are 
thinner and not suitable to the lumen size, often fenestrated, thereby 
increasing permeability to macromolecules and cells that can pass 
through it. The transport of fluids and molecules into the interstitium is 
tightly modulated by interstitial compartment’s biological and physical 
properties and by the physical and chemical properties of the molecules. 
The composition of interstitial compartment within neoplastic tissues is 
significantly different from normal tissues: it presents wide interstitial 
spaces, high collagen concentration, low proteoglycan and hyaluronic 
acid levels, high macromolecule diffusion coefficients and lacks a 
functional lymphatic network leading to a high interstitial pressure. The 
high interstitial fluid pressure affects the normal hydrostatic gradient that 
reduces convective movements, thus delaying macromolecule passage 
trough fenestrations (Jain, 1999). This unusual behaviour of fluid 
movement in and out of tumor blood vessel reflects the particular wall 
composition (McDonald and Baluk, 2002). The endothelial cells do not 
constitute a normal monolayer, but have an irregular shape, are 
disorganized, accumulate in multilayer and are weakly bound to each 
other. Recruited pericytes and the basal membrane are disorganized and 
weakly associated to endothelial cells (Morikawa et al., 2002). 
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Weak interactions favour the destabilized state of vessels which are thus 
prone to angiogenic sprouting. Tumor vessels are in fact immature, since 
maturation would lead to a quiescent status. This underlies the 
conventional description of tumor vessels as constantly bleeding. 
Immunoistochemestry and ultrastructural analyses showed that tumor 
cells may be involved in blood vessel architecture participating in vessel 
lining and creating a mosaic vessel (Folberg and Maniotis, 2004; Zhang 
et al., 2007). 
The abnormal features of the tumor vasculature are belived to result 
from the alteration of the angiogenic balance between pro- and anti-
angiogenic signals (Bergers and Benjamin, 2003). During normal 
physiological angiogenesis, new vessels rapidly mature and become 
stable. By contrast, tumors lose the appropriate balances between 
positive and negative controls, resulting in a disproportionate expression 
of angiogenic cytokines and inhibitors. A classical model of the 
regulation of angiogenesis is illustrated by a scale laden with anti-
angiogenic molecules on one side and pro-angiogenic molecules on the 
other (Bergers and Benjamin, 2003). Induction of the angiogenic switch 
depends on how heavily that balance tips in favour of pro-angiogenesis. 
Tumor is one of the best known condition in which angiogenesis is 
switched on. Several studies demonstrate that tumor cells induce 
angiogenesis through the secrection of pro-angiogenic factors. 
Moreover, the inhibition of these factors may cause a decrease of tumor 
vascularization and consequent reduction of tumor growth (Ribatti et al., 
2007). The vascular endothelial growth factors, in particular VEGF-A, 





1.1.3 Angiogenic growth factors and their receptors  
New vessel growth and maturation are highly complex and coordinated 
processes requiring the sequential activation of a series of receptors by 
numerous ligands in endothelial and mural cells (Carmeliet, 2003; Jain, 
1999). Many evidences indicate that tumor cells secrete pro-angiogenic 
growth factors that bind to receptors on dormant endothelial cells (ECs), 
leading to vasodilation and an increase in vessel permeability (Bergers 
and Benjamin, 2003; Carmeliet, 2003). The growth factors can also act 
on more distant cells recruiting bone marrow-derived precursor ECs and 
circulating ECs to migrate to the tumor vasculature (Bergers and 
Benjamin, 2003; Carmeliet, 2003).  
Many potential angiogenic factors have been described over the past two 
decades (Klagsbrun, 1991; Yancopoulos et al., 2000) and many 
evidences indicate how vascular endothelial growth factors (VEGFs) is 
an important regulator family for angiogenesis (Ferrara, 2002).  
The VEGF family comprises seven proteins that are designated VEGF-A 
(Ferrara et al., 2003), VEGF-B (Stein et al., 1998) and PlGF (Placental 
Growth Factor), (Maglione et al., 1991) involved in angiogenesis, 
VEGF-C (Barleon et al., 1997; Gerber et al., 1997), VEGF-D (Hood et 
al., 1998; Waltenberger et al., 1996) that take place in 
lymphagiogenesis, VEGF-E (Meyer et al., 1999; Ogawa et al., 1998) 
and VEGF-F (Suto et al., 2005) recently isolated which biological 
function are not well known. The VEGFs exert their biologic effect 
through the interaction with specific tyrosine kinases receptors that are 
designed VEGFR-1 (also known Flt-,fms-like tyrosine kinase) (Masuda 
et al., 1990), VEGFR-2 (named KDR (kinase domain receptor) in 
human and Flk-1 (Fetal liver kinase-1) in mouse) (Matsumoto and 
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Claesson-Welsh, 2001), VEGFR-3 (also known Flt-4) (Pajusola et al., 
1994). VEGF-A binds to both receptors Flt-1 and KDR/Flk-1 inducing 
vasculogenesis and angiogenesis. In contrast, PlGF and VEGF-B bind 
exclusively to Flt-1. PlGF acts on a wide range of cell types, stimulating 
the growth, migration and survival of endothelial cells (Adini et al., 
2002; Carmeliet et al., 2001), increasing the proliferation of fibroblasts 
and smooth-muscle cells (Bellik et al., 2005), inducing vasodilatation 
and stimulating collateral vessel growth (Bellik et al., 2005). It also 
promotes the recruitment and maturation of angiogenesis- competent 
myeloid progenitors to growing sprouts and collateral vessels (Hattori et 
al., 2001).  
Many other regulatory and signalling molecules govern the angiogenesis 
process (Ribatti et al., 2000).  
The family of platelet-derived growth factors (PDGFs) and its receptors 
PDGFR-α and PDGFR-β are involved in vessel maturation and the 
recruitment of pericytes (Lindahl et al., 1997), stimulating angiogenesis 
in vivo (Oikawa et al., 1994; Risau et al., 1992). PDGF is expressed by 
ECs and generally acts in a paracrine manner, recruiting PDGFR-
expressing cells, particularly pericytes and smooth muscle cells to the 
developing vessels (Andrae et al., 2008).  
The mammalian fibroblast growth factors (FGFs) and their receptor are 
widely expressed and present on most cell types, in which they act 
through a wide range of biological roles (Cao et al., 2008). In EC culture 
and animal models they lead to angiogenesis promoting the 
proliferation, migration, and differentiation of vascular ECs (Abraham et 
al., 1986; Maciag et al., 1984). 
The EGF/EGFR (epidermal growth factor/epidermal growth factor 
receptor) system plays an indirect role in angiogenesis up-regulating the 
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production of pro-angiogenic factors such as VEGF. Activation of 
EGFR has been linked to angiogenesis in xenograft models in addition 
to metastasis, cell proliferation, survival, migration, transformation, 
adhesion, and differentiation (Perrotte et al., 1999; Yarden and 
Sliwkowski, 2001). 
Transforming growth factor-β (TGF-β) and corresponding receptors 
participates in angiogenesis, cell regulation and differentiation, 
embryonic development, and wound healing (Blobe et al., 2000). TGF-β 
is believed to have both pro-angiogenic and anti-angiogenic properties, 
depending on the levels present. Low levels of TGF-β contribute to 
angiogenesis by up-regulating angiogenic factors and proteases, whereas 
high doses of TGF-β stimulate basement membrane reformation, recruit 
smooth muscle cells, increase differentiation, and inhibit EC growth 
(Carmeliet, 2003). 
Hepatocyte growth factor (HGF) is a potent mitogenic, motogenic and 
morphogenic factor with angiogenic properties. The HGF/Met signalling 
directly or indirectly stimulate endothelial cells by activating angiogenic 
pathways (Dong et al., 2001; Sengupta et al., 2003), regulating other 
angiogenic factors (Zhang et al., 2003) or mobilizing endothelial 
progenitor cells (Schroder et al.). 
Because growth factors stimulate ECs, leading to angiogenesis, the 
growth factors, receptors, and subsequent signalling cascades make for 
promising targets in angiogenesis inhibition. Significant progress in 
targeting these pathways has been made, and several drugs have been 
approved by the Food and Drug Administration (FDA) or are currently 





1.1.4 Modern approach in angiogenesis inhibition 
The inhibition of angiogenesis and vascular targeting has been in the last 
decade the focus of new treatment strategies against the cancer. 
Numerous new substances, such as recombinant proteins and 
monoclonal antibodies, synthetic or natural origin compounds, were 
assessed as angiogenesis inhibitors and evaluated in clinical trials for 
safety, tolerance, and efficacy. Some of these molecules have already 
been approved for various indications, such as the VEGF neutralizing 
antibody Bevacizumab (Avastin) currently tested in several hundred 
clinical trials in a variety of different tumor types (Database of Current 
Clinical Trials, 2009). Bevacizumab is a humanized monoclonal 
antibody that binds to VEGF-A, preventing it from binding to receptors 
and activating signalling cascades that lead to angiogenesis. The use of 
Bevacizumab in combination with irinotecan, fluorouracil (5-FU), and 
leucovorin in patients with metastatic colorectal cancer significantly 
increased the progression free survival (PFS), as well as the median 
overallsurvival (OS) (Hurwitz et al., 2004). Bevacizumab did not 
provide any benefit for patients with metastatic breast cancer when used 
in combination with capecitabine (Miller et al., 2005), whereas 
increased the PFS and OS in combination with paclitaxel (Miller et al., 
2007). However, there was still no significant increase noted in OS, as 
had been observed with colorectal cancer (Hurwitz et al., 2004) and non-
small-cell lung cancer (NSCLC) (Johnson et al., 2004; Sandler et al., 
2006). Actually Bevacizumab is approved for various indications in 
colorectal cancer, NSCLC, breast cancer, renal cell carcinoma (RCC), 
and glioblastoma (Cook and Figg). 
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Other anti-angiogenic drugs targeting multiple tyrosine kinase receptors, 
defined tyrosine kinase inhibitors (RTKIs), have been approved (Cook 
and Figg). The small-molecules Sunitinib and Sorafenib, are tyrosine 
kinase inhibitors targeting the VEGF receptor, primarily VEGFR-2, and 
have shown clinical efficacy in diverse cancer types (Gan et al., 2009; 
Wilhelm et al., 2008). Both drugs have shown benefit in patients with 
renal cell cancer (Escudier et al., 2009; Motzer et al., 2006). Sorafenib 
inhibits Raf serine kinase and has been approved for treatment of 
hepatocellular cancer (Llovet et al., 2008). 
Erlotinib (OSI-774) is an oral inhibitor of the EGFR/HER1 RTK that is 
approved by the FDA for NSCLC patients who have failed 
chemotherapy (Shepherd et al., 2005) and for pancreatic cancer patients 
when used in combination with gemcitabine (Moore et al., 2007). 
Imatinib (STI571) inhibits the cytoplasmic and nuclear protein tyrosine 
kinase Abl, as well as the RTK PDGFR and c-kit and has been used 
extensively in the treatment of chronic myelogenous leukemia (CML) 
(Mahon et al.).  
Additional RTK inhibitors are currently in clinical trials for a variety of 
cancers (Heath and Bicknell, 2009) (Table 3).  
While these drugs have provided new ways to treat cancer, the survival 
benefits of these treatments are relatively modest, further, they are costly 
and can have toxic side effects (Eskens and Verweij, 2006; Kerbel, 
2008; Verheul and Pinedo, 2007). Intrinsic and acquired resistance to 
anti-angiogenic drugs are becoming clinically significant problems; pre-
clinical studies have begun to shed light on potential mechanisms of 
resistance. Murine tumor cell lines intrinsically resistant to anti-VEGF 
antibodies have been shown to be colonized by bone marrow derived 
myeloid-suppressor cells in vivo (Shojaei et al., 2009). These myeloid 
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cells then make an alternative angiogenic factor, Bv8 (Shojaei et al., 
2009), which circumvents the VEGF blockade. Moreover, when anti-
VEGF sensitive tumor cells are mixed with myeloid cells from treatment 
resistant tumors, these myeloid cells confer resistance (Shojaei et al., 
2009). Acquired resistance to VEGF pathway inhibitors can be caused 
by the redundancy of angiogenesis stimulators. An example is up-
regulation of the angiogenesis stimulator basic fibroblast growth factor 
(bFGF) within the tumor after treatment with anti-VEGF therapy, which 
may also act synergistically with other angiogenic factors such as PDGF 
isoforms (Kerbel, 2008). Disruption of other angiogenesis-associated 
pathways may paradoxically enhance angiogenesis itself (Reynolds et 
al., 2009). Recent studies have suggested that hypoxia induced by VEGF 
blockades enhances tumor cell migration, invasion and metastatic 
dissemination (Ebos et al., 2009; Paez-Ribes et al., 2009) by up-
regulating activity of the HGF/Met pathway in tumor cells, which 
subsequently (Pennacchietti et al., 2003). These observations underline 
the importance of finding new agents able to modulate pathological neo-
angiogenesis through selective pathways. Recently, the HGF/Met axis 
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INHIBITOR  OTHER NAMES  INHIBITS 
Axitinib  AG013736  VEGFR, PDGFR, and c-kit 
Canertinib   CI-1033 EGFR, HER2, HER3, and HER4 
Cediranib   Recentin, AZD2171 EGFR, PDGFR-β, and c-kit 
Dasatinib  Sprycel, BMS-354825 Abl, Src, and Tec 
Erlotinib Tarceva, OSI-774 EGFR/HER1 
Gefitinib  Iressa EGFR/HER1 
Imatinib Gleevec, STI571  Abl, PDGFR, and c-kit 
Lapatinib  Tykerb, GW-572016  EGFR and HER2 
Leflunomide   Arava, SU101 PDGFR (EGFR and FGFR) 
Motesanib   AMG 706 VEGFR, PDGFR, and c-kit 
Neratinib  HKI-272 EGFR and HER2 
Nilotinib  Tasigna  Abl, PDGFR, and c-kit 
Pazopanib  Armala, GW786034  VEGFR, PDGFR-α and -β, and c-kit 
Regorafenib  BAY 73-4506 VEGFR-2 and Tie-2 
Semaxinib  SU5416  VEGFR 
Sorafenib Nexavar, BAY 43-9006 
Raf, VEGFR-2 and -3, PDGFR-β, 
and c-kit 
Sunitinib   Sutent, SU11248 
VEGFR, PDGFR, Flt-3, c-kit, RET, 
and CSF-1R 
Tandutinab   MLN518, CT53518 PDGFR, Flt-3, and c-kit 
Vandetanib   Zactima, ZD6474 
VEGFR-2, PDGFR-β, EGFR, and 
RET 




1.2 Hepatocyte growth factor and its receptor Met 
The receptor for the human hepatocyte growth factor (HGF) Met is a 
proto-oncogene located on chromosome 7 band 7q21–q31 and spans 
more than 120 kb in length. The protein is synthesized as a 170 kDa 
precursor which is glycosylated and proteolytically cleaved into a 50 
kDa α-chain and a 140 kDa β-chain with a large extracellular region 
(involved in binding the ligand), a membrane spanning segment, and an 
intracellular region (containing the catalytic activity). The α and β chains 
are disulphide linked. The extracellular portion of Met contains a region 
of homology to semaphorins (Sema domain, which includes the full α 
chain and the N-terminal part of the β chain of Met), a cysteine rich Met 
Related Sequence (MRS) followed by glycineproline- rich (G-P) repeats, 
and four Immunoglobuline-like structures (Birchmeier et al., 2003). The 
intracellular region of Met contains three regions: (1) a juxtamembrane 
segment that contains: (a) a serine residue (Ser 985) that, when 
phosphorylated by protein kinase C or by Ca2+calmodulin-dependent 
kinases downregulates the receptor kinase activity (Gandino et al., 
1994); and (b) a tyrosine (Tyr 1003) that binds the ubiquitin ligase Cbl 
responsible for Met polyubiquitination, endocytosis and degradation 
(Peschard et al., 2001); (2) the tyrosine kinase domain that, upon 
receptor activation, undergoes transphosphorylation on Tyr1234 and 
Tyr1235; (3) the C-terminal region, which comprises two crucial 
tyrosines (Tyr1349 and Tyr1356) inserted in a degenerate motif that 
represents a multisubstrate docking site capable of recruiting several 
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Figure 3: Structure of Met 
 
Hepatocyte growth factor is a member of the plasminogen related 
growth factor family. It is produced as inactive molecule, pro-HGF, 
which is subsequently cleaved to its active form by proteases such as the 
urokinase-type plasminogen activator and the tissue-type plasminogen 
activator (Maina et al., 1996; Ponzetto et al., 1994; Zanetti et al., 1998), 
and by coagulation factors X, XI and XII. The mature form of HGF is a 
disulphide bound α–β heterodimer. It consists of a harpin loop, four 
Kringle domains (K1–K4) in the α-chain, and a serine protease 
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Figure 4: Structure of HGF 
 
Met is predominantly expressed by epithelial cells (Di Renzo et al., 
1991; Prat et al., 1991), although it is also expressed in other cell types, 
including endothelial (Bussolino et al., 1992), myoblasts (Anastasi et al., 
1997), hematopoietic (Nishino et al., 1995) and neuronal cells (Ebens et 
al., 1996). HGF is expressed only by cells of mesenchymal origin 
(Zarnegar, 1995). 
Ligand binding triggers receptor activation through dimerization and 
auto/trans-phosphorylation of tyrosine residues. Two tyrosine residues 
within the catalytic loop (Y1234, Y1235) are first to be phosphorylated, 
leading to full kinase activation (Longati et al., 1994). Subsequently, 
two other tyrosine residues (Y1349, Y1356) in the carboxyl-terminal tail 
are phosphorylated. These are embedded in a multifunctional consensus 
sequence (Ponzetto et al., 1994), acting as a docking site for different 
SH2-containing transducers and adaptors involved in several pathways, 
including the GRB2–SOS–RAS–RAF–MEK–ERK (extracellular signal 
regulated protein kinase) pathway, the phosphoinositide 3-kinase–AKT 
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cascade, SRC, STAT3, SHC, PLC-g, cbl, Gab1 and Rho-like GTPases 
such as RAC1 (Birchmeier et al., 2003; Lock et al., 2003). These signals 
direct a variety of cellular responses, such as cell proliferation, survival, 
motility and angiogenesis which occur during the invasive growth 
(Comoglio and Trusolino, 2002). 
 
1.2.1 Met and the invasive growth: from development to metastasis 
Invasive growth is a complex morphogenetic program characterized by 
independent events such as migration, survival, matrix degradation, and 
induction of cell polarity that occurs both during embryonic 
development and during adult life (Figure 5). During tissue and organ 
morphogenesis, normal cells colonize new territories and build polarized 
three-dimensional structures, thus forming the parenchymal architecture 
of several organs. Similarly, by the invasive growth, the angioblasts 
cluster and reorganize to form capillary-like structures during 
vasculogenesis, and new capillaries sprout from pre-existing vessels 
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Figure 5: The invasive growth program under physiological and pathological 
conditions. In both settings, invasive growth results from analogous biological 
processes but the endpoints are different. Normal cells exploit invasive growth 
to form the parenchymal architecture of several organs. Cancer cells 
implement this program aberrantly to infiltrate the adjacent surroundings and 
form metastases. 
 
During development, Met is required for development of the placenta, 
liver, kidney, neuronal, and skeletal muscle. In adults, Met expression 
plays a role in hematopoiesis (Ikehara, 1996; van der Voort et al., 2000) 
including B-cells development during antigen selection (van der Voort et 
al., 2000; van der Voort et al., 1997) and tissue injury. In some 
instances, such as the growth and development of the liver, Met 
signalling induces proliferation and survival.  
Under pathological conditions, invasive growth is responsible for cancer 
progression and metastasis (Birchmeier et al., 2003; Comoglio and 
Trusolino, 2002). Cancer cells implement the program aberrantly to 
invade the adjacent compartments, overstepping the physical barriers 
and colonizing new territories where they may migrate, proliferate, and 
survive. In tumor progression Met may induce different phenotype 
depending on tumor stage: activating proliferation in primary tumors, 
stimulating motility to form micrometastases, and inducing the 
angiogenic phenotype to form metastases (Gao and Vande Woude, 
2005).  
The angiogenic properties of Met and its ligand are related to their 
capability to stimulate endothelial cell migration, proliferation and 
organization into capillary-like tubes (Bussolino et al., 1992; Grant et 
al., 1993; Silvagno et al., 1995). In particular, HGF can induce pro-
angiogenic cytokine expression, directly activating angiogenic pathways 
(Dong et al., 2001; Sengupta et al., 2003) or downregulating the 
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expression of angiogenic inhibitors (Zhang et al., 2003) and promoting 
lymphangiogenesis (Cao et al., 2006). Together, these activities favour 
tumor expansion, the release of neoplastic emboli into the bloodstream 
and Met activation in cancer cells.  
The oncogenic potential of Met has been documented in a variety of 
human cancers and many of them appear to be dependent on receptor 
activity for their growth and survival. Inappropriate activation of Met 
can be induced by specific genetic alterations, ligand-dependent 
autocrine or paracrine mechanisms and receptor overexpression. Met-
activating mutations are found in hereditary kidney cancer and in 
sporadic papillary renal cancer, childhood hepatocellular carcinoma, and 
gastric cancer (Lee et al., 2000; Park et al., 1999; Schmidt et al., 1997). 
An autocrine or paracrine mechanism of Met activation has been 
reported in tumors derived from mesenchymal cells, such as 
osteosarcomas and rhabdomyosarcomas and from ectodermal tissues 
such as glioblastomas and breast carcinomas (Ferracini et al., 1995; 
Ferracini et al., 1996; Koochekpour et al., 1997; Tuck et al., 1996). Met 
overexpression is the most frequent event in human tumors and it is 
associated with a metastatic phenotype and a poor prognosis (Di Renzo 
et al., 1995; Houldsworth et al., 1990; Miller et al., 2006; Tong et al., 
2004).  
Since Met signalling contributes to tumor survival, growth, angiogenesis 
and metastasis, it provides a potential target for cancer therapy. 
 
1.2.2. Met receptor as a therapeutic anticancer target 
Different strategies to target Met have the aim of inhibiting tumor 
growth and metastatic dissemination (Comoglio et al., 2008). Numerous 
agents have been developed and are able to target Met expression and/or 
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activation (Figure 6). Agents which inhibit Met expression target both 
ligand-dependent and -independent activation by reducing the levels of 
active Met to below threshold levels. The transcription inhibitors block 
RNAPII phosphorylation, prematurely terminate transcription and 
inhibit polyadenylation. Flavopiridol, a semi-synthetic flavonoid, 
inhibits mRNA transcription by blocking transcription elongation 
through the inhibition of Cdk9/ cyclin T (Chao and Price, 2001). The 
adenosine analog, 8-chloro-adenosine (8-Cl-Ado), is able to inhibit 
transcription by incorporating the triphosphate form of the analog into 
primarily mRNA and prematurely terminating transcription (Stellrecht et 
al., 2003) as well as its likely inhibition on poly(A) polymerase activity 
(Chen and Sheppard, 2004). The polyadenylation inhibitor, cordycepin, 
inhibited RNA synthesis and lead to the induction of apoptosis (Chen et 
al., 2008). Gene silencing based on antisense, ribozyme and RNA 
interference techniques have been also used experimentally to silence 
Met and HGF expression (Chu et al., 2009; Corso et al., 2008; Paranjpe 
et al., 2007). 
Hsp90 inhibitors such as Benzoquinone ansamycin antibiotics, including 
geldanamycin and its derivative 17-allylamino-17-
demethoxygeldanamycin (17-AAG), inhibit Met protein stability, 
preventing its folding and leading to its destabilization (Webb et al., 
2000; Xie et al., 2005). 
The mature Met protein can be blocked by small molecule inhibitors, 
early examples for which are K252a (Morotti et al., 2002), SU11274 
(Berthou et al., 2004) and PHA-665752 (Christensen et al., 2003), all of 
which compete for ATP binding to block Met catalytic activity. Several 
of these molecules (PF-2341066, XL880, ARQ197, MK2461, MP470, 
SGX523 and JNJ38877605) are in phase I/II clinical trials (Comoglio et 
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al., 2008; Zou et al., 2007). Owing to the way in which they were 
selected and the inhibitory mechanism with which they operate, none of 
these drugs shows absolute specificity for Met, but also target other 
kinases, mostly receptor tyrosine kinases (Comoglio et al., 2008). 
Higher levels of specificity in Met inhibition can be obtained using 
biological molecules, either natural or designed expressly on the basis of 
the structure of HGF or Met. They act as antagonists that interfere in the 
ligand/receptor interaction, which normally leads to receptor 
dimerization and subsequent activation. HGF can be antagonized by its 
shorter forms: NK2—a natural fragment of HGF, or NK4—a truncated 
form of HGF, or by its uncleavable form, all of which bind the receptor 
but cannot fully activate it (Chan et al., 1991; Matsumoto and 
Nakamura, 2003; Mazzone et al., 2004). Similarly, anti-HGF-
neutralizing antibodies act by subtracting functional HGF in the 
microenvironment (Cao et al., 2001), some of which are in pre-clinical 
or phase II clinical trials (Jun et al., 2007; Kim et al., 2006), whereas 
decoy Met, a soluble truncated Met extracellular receptor domain, both 
sequesters the ligand and impairs receptor dimerization (Michieli et al., 
2004). The main limit of using HGF inhibitors is that they only inhibit 
HGF-dependent receptor activation. Few antagonist anti-receptor 
monoclonal antibodies are available; these antibodies tend to have 
agonistic rather than antagonistic properties due to their bivalent 
structure (Prat et al., 1998). One promising monoclonal antibody, DN-
30, is able to downregulate Met and inhibit tumor growth in 
experimental models (Vigna et al., 2008). Additional strategies to target 
Met signalling are aimed at Met co-receptors, such as CD44, the α6β4 
integrin and B plexins (Bertotti and Comoglio, 2003). The inactivation 
of co-receptors could be obtained by designing antibodies or peptides 
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that disrupt the Met-based heterocomplexes. It has been demonstrated 
that a peptide fragment of CD44 prevents activation of Met-triggered 
signals and Met-induced migration in vitro (Matzke et al., 2005). 
Finally, peptides interfering with the association of signal transducers to 
the Met receptor docking site could block the propagation of Met 
signalling. Previous studies have shown that a peptide derived from the 
carboxyl-terminal tail of Met specifically inhibited kinase activity and 
HGF-induced invasive growth in normal and transformed epithelial cells 
in vitro (Bardelli et al., 1999) and enhanced the chemosensitivity of 
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2. Aim of the Project 
 
The purpose of this project has been the identification of new agents 
able to modulate pathological neo-angiogenesis through selective 
pathways, overcoming or delaying the phenomena of resistance and 
toxicities observed during the anti-angiogenic treatment. Due to the 
emerging role of Met receptor and its specific ligand HGF in many 
aspects of cancer development and progression, Met could be considered 
a strong candidate for targeted therapy. 
We decided to develop angiogenesis inhibitors that target the Met 
invasion pathway. The therapeutic inhibition of Met activity to prevent 
the potential dissemination of cancer cells targeting angiogenesis, 
suggests the use of Met inhibitors as a combination therapy that 
concomitantly impairs metastatic spreading and tumor neo-
vascularization.  
 
Accordingly to this, the research project has been mainly focused on the 
following objectives: 
i. to design synthetic Met-derived peptides mimicking the docking 
site of the receptor; 
ii. to characterize at cellular and molecular level the mechanisms of 
action of the peptides; 
iii. to evaluate in vitro and in vivo their anti-angiogenic activity; 







Peptides were delivered into cells by fusion with the internalization 
sequences from either the Antennapedia homeodomain (Antp) or HIV-
Tat previously shown to translocate peptides efficiently across the 
plasma membrane (Deshayes et al., 2005; Foged and Nielsen, 2008; 
Gupta et al., 2005; Morris et al., 2008; Stewart et al., 2008).  
The plasma membrane of eukaryotic cells constitutes an impermeable 
barrier for many molecules, thus, molecular transporters have been 
developed to facilitate the passage of pharmaceutically-active agents 
into living cells. Among them, much attention has recently been given to 
the use of peptide-based delivery systems (Deshayes et al., 2005). These 
peptides, called cell-penetrating peptides (CPPs), are short peptides 
(fewer than 30 residues) with a net positive charge and acting in a 
receptor- and energy-independent manner. Compared with other 
delivery systems, such as cationic lipids (Kawakami et al., 2004; 
Zelphati and Szoka, 1996) or polyethyleneimine (PEI) (Zaric et al., 
2004; Zou et al., 2000), the use of peptides with cell-penetrating 
properties has several advantages; there is a rapid delivery of cargoes 
into cells with very high efficiency, stability in physiological buffers, 
lack of toxicity and sensitivity to serum. Moreover, CPPs avoid the 
endosomal pathway and favour the escape of the cargo from early 
endosomes (Morris et al., 2008).  
Many CPPs were designed from sequences of membrane interacting 
proteins, such as fusion proteins, signal peptides and transmembrane 
domains. Within these sequences, short sequences called protein 
transduction domains (PTDs) proved to efficiently cross biological 
membranes and to deliver peptides or proteins into intracellular 
compartments (Schwarze and Dowdy, 2000). Among these, the third 
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helix of the homeodomain of Antennapedia called Penetratin (Derossi et 
al., 1994) and the Tat peptide derived from the transactivating protein 
Tat of human immunodeficiency virus-type 1 (HIV-1) (Fawell et al., 
1994), were used to improve the cellular uptake of peptides, proteins and 
oligonucleotides. 
In our study we used alternatively both Penetratin and Tat sequences 
fused to Met-derived peptides for their delivery into endothelial cells. 
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3. Material and Methods 
 
3.1. Reagents 
Murine recombinant VEGF-A, human recombinant VEGFA165, murine 
recombinant tumor necrosis factor-α (TNF-α) and human recombinant 
HGF in its biologically active form (Gherardi et al., 2006) were 
purchased from Peprotech (Offenbach, Germany); heparin was obtained 
from Sigma (Sigma-Aldrich Chemie, Taufkirchen, Germany). Matrigel 
was prepared from the Engelbreth–Holm–Swarm sarcoma as described 
previously (Kleinman et al., 1986). 
Cell-permeable peptides containing the Met docking site sequence (ref. 
seq: NP_000236), or a control scrambled sequence, fused to the 
internalization sequences of either the homeodomain 3 of the 
Antennapedia protein (ref. seq: NP_996167) or the Tat transactivator 
domain (ref. seq: NP_057853) at their N-terminus were synthesized and 
purified by Primm (Milan, Italy). Two Tat sequences of different lengths 
were used. Peptides conjugated to FAM (5-(and-6)-carboxyfluorescein) 
at their N-terminus were used to evaluate internalization. Peptide 





Tat-Met GRKKRRQRRRPP IGEHYVHVNATYVNVKCVA 




Table 4: Sequences of cell-permeable peptides derived from the Met receptor 
docking site fused to internalization sequences from the Antennapedia and Tat 





3.2. Cell cultures 
Human umbilical vein endothelial cells were purchased from Promo Cell 
(Heidelberg, Germany) and grown on 1% gelatine-coated tissue culture 
plates in M199 endothelial growth medium (Sigma, St Louis, MO, 
USA), supplemented with 10% heat-inactivated FBS (fetal bovine 
serum), 1% L-glutamine, fibroblast growth factors (1 mg acid-fibroblast 
growth factor plus 1 mg basic-fibroblast growth factor /100 ml), 
epidermal growth factor (1 mg/100 ml), heparin (10 mg/100 ml) and 
hydrocortisone (0.1 mg/100 ml). Cells were used between the second 
and eighth passage in vitro. The murine lung endothelial cell line (1G11) 
was the kind gift from Annunciata Vecchi (Istituto Clinico Humanitas, 
IRCCS and University of Milan, Milan, Italy). 
 
3.3. Cytofluorimetric analysis 
Human umbilical vein endothelial cells (6x105) were incubated with 10 
µM concentrations of FAM-labeled peptides for different periods of 
time (10, 30, 60 and 120 min). Cells were then recovered, washed twice 
with phosphate-buffered saline (PBS), fixed in 4% paraformaldehyde 
and analyzed by flow fluorocytometry in a FACSCanto (BD 
Biosciences, San Jose, CA, USA).  
To compare the effect of our peptides with that of the Met specific 
inhibitor PHA-665752 (the kind gift of Professor Livio Trusolino, Univ. 
Torino), 1x10
5
 HUVECs were plated in six-well plates and allowed to 
adhere overnight. The next day, the cells were treated in the growth 
medium (in the presence of HGF 50 ng/ml or 10% FBS) with the Antp-
Met peptide (10 µM), Tat-Met peptide (10 µM) or Tat s-Met peptide (10 
µM) or with increasing concentrations of PHA-665752 (250 and 500 
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nM, and 1 and 5 µM). Dimethyl sulfoxide and growth medium alone (in 
the presence of HGF 50 ng/ml or 10% FBS) were used as controls. After 
2 h, cells were recovered, washed with PBS and transferred to test tubes. 
Cells were pelleted and resuspended in Annexin V-binding buffer 
(0.01M HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
(pH 7.4); 0.14M NaCl; 2.5mM CaCl2). Fluorescein isothiocyanate 
Annexin V and 7-amino-actinomycin D (BD Biosciences) were added to 
each test tube and incubated for 15 min at room temperature in the dark. 
Cells were then washed in PBS, supernatants discarded and resuspended 
in 400 ml of binding buffer. Samples were acquired by flow 
fluorocytometry using a FACSCanto (BD Biosciences) and analyzed 
using FACSDiva Software 6.1.2. The experiment was performed three 
times and each condition was a triplicate. 
 
3.4. Immunofluorescence analysis 
HUVE cells were seeded at subconfluency in gelatine 0.1%-coated 8-
well chamber slides in complete medium and then treated with 10 µM of 
each labelled-peptide. After 2 hours, cells were washed twice with PBS 
and fixed with 4% paraformaldehyde. After excitation at 488 nm, green 
fluorescent images of the internalised peptides were visualized by 
confocal microscopy (Leica TCS SP, Leica Lasertechnik, Heidelberg, 
Germany).  
 
3.5. In vitro cell viability 
Human umbilical vein endothelial cell viability was evaluated in the 
MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
assay. MTT is a substrate of mitochondrial reductase enzyme that is 
reduced to purple formazan in living cells. The absorbance of the 
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colored solution can be quantified by a spectrophotometer and is directly 
consistent with the mitochondrial activity. 
Cells (1000/well) were seeded in gelatine 0.1%-coated 96-well plates in 
100 µL complete medium. After complete adhesion, the medium was 
replaced with 2% FBS fresh medium with or without 50 ng/ml HGF 
and/or different peptides at different concentrations (1–50 µM) or with 
or without PHA-665752 at increasing concentrations (250 nM–10 µM). 
After the indicated times of incubation (24, 48, 72 and 96 h) 10µl/well 
of MTT (5mg/ml) were added to cells and after 3 hours, 100 µl of 
solubilization solution (3.7% HCl, 10% SDS) were used to dissolve 
formazan products. The plates were then read with a spectrophotometer 
at 570 nm wavelength.  
 
3.6. Migration assay 
Cell migration assays were performed in modified Boyden chambers as 
previously described (Albini and Benelli, 2007; Albini et al., 1987).  
Endothelial cells (5x10
4
) were washed with PBS, resuspended in serum-
free medium, and placed in the upper compartment. The two 
compartments of the Boyden chamber were separated by 12 µm pore-
size polycarbonate filters coated with 50 µg/ml of collagen. Fifty ng/ml 
HGF or 10 ng/ml VEGF diluted in serum-free M199 medium were used 
as chemoattractants in the lower chamber compartment and the different 
peptides or PHA-665752 at different concentrations were added to the 
cells. After 6 hours of incubation at 37°C in 5% CO2, filters were 
recovered and cells on the upper surface were mechanically removed. 
Cells migrated to the lower filter surface were fixed with 99,8% ethanol, 
stained with toluidine blue and counted in double-blind manner in five to 
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eight consecutive fields for each sample under a microscope. Each test 
was performed in triplicate and repeated three times. 
 
3.7. Invasion assay 
Endothelial cells were washed with PBS, resuspended in serum-free 
medium, and subjected to cell invasion assays using Boyden chambers 
as previously described (Albini and Benelli, 2007; Albini et al., 1987).  
Fifty ng/ml HGF diluted in serum-free M199 medium was used as 
chemoattractant. Invasion was performed using 12 µm pore-size 
polycarbonate filters pre-coated with 1mg/ml matrigel. Cells (5x10
4
) 
were seeded in the upper compartment with or without the different 
peptides. At the end of the overnight incubation, cells remaining at the 
upper surface of the filter were mechanically removed. Cells migrated to 
the lower filter surface were fixed with 99,8% ethanol, stained with 
toluidine blue and counted in double-blind manner in five to eight 
consecutive fields for each sample under a microscope. Each test was 
performed in triplicate and repeated three times. 
 
3.8. Morphogenesis assay 
The assay was performed as described by (Grant et al., 1989) A 
prechilled 24-well plate was carefully filled with liquid matrigel (10 
mg/ml; 300µl/well) at 4°C, which was then polymerized for 1 hour at 
37°. Cells (50,000/well) were suspended in serum free medium in 
presence of 50 ng/ml HGF or 10% FBS and with the peptides or PHA-
665752 in increasing concentrations; this suspension was carefully 
layered on the polymerized matrigel. After 6 h incubation, the three 
dimensional organization of the cells was examined under an inverted 
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microscope (Zeiss, Oberkochen, Germany) equipped with CCD optics 
and a digital analysis system. 
 
3.9. Western blotting 
Human umbilical vein endothelial cells, pre-incubated in serum-free 
medium for 24 h, were pre-treated for 2 h with 10 µM Antp-Met peptide 
before stimulation with 10 ng/ml HGF for 15 min (Prat et al., 1998). 
Lysates were prepared using Cell Lysis Buffer (Cell Signaling 
Technology, Beverly, MA, USA) and protein concentrations evaluated 
by the DC Protein Assay (Bio-Rad, Hercules, CA, USA). Proteins were 
separated on 8% SDS–polyacrylamide gel electrophoresis under 
reducing conditions and transferred onto polyvinylidene fluoride 
membranes (Amersham, Biosciences, Otelfingen, CH, USA), which 
were then incubated with the antibodies directed against the following 
human antigens: phospho-ERK1/2, tubulin, phospho-Met (tyrosine 
1349), phospho-Met (tyrosines 1234–1235) (Cell Signaling Technology) 
and Met (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) diluted 
in 5% bovine serum albumin–Tris-buffered saline–0.1% Tween. 
Horseradish-peroxidase-conjugated secondary antibodies against rabbit 
or anti-mouse immunoglobulin (Cell Signaling Technology; 1:5000) 
were then used and reactions were visualized with the enhanced 
chemiluminescence kit (ECL) from Amersham Biosciences (Pittsburg, 
PA, USA). Lysates HUVEC and 1G11 cells were incubated with 
antibodies directed against human Met and mouse Met (both provided 






3.10. In vivo matrigel sponge assay 
The assay was performed as described (Albini et al., 1994). HGF (50 
ng/ml in the presence of heparin 50 U/ml), with or without peptides, was 
added to unpolymerized liquid matrigel and slowly injected 
subcutaneously into the flanks of 6- to 8-week-old C57/BL6 male mice 
(Charles River Laboratories, Calco (Lecco), Italy) in groups of 4–8 mice 
for each treatment. Four days after injection, the animals were killed and 
the pellets were removed, weighed, and either formalin-fixed and 
paraffin-embedded for histological examination, or minced and diluted 
in water for hemoglobin content measurement with a Drabkin reagent kit 
(Sigma). The final haemoglobin concentration was calculated from a 
standard calibration curve, after spectrophotometric analysis at 540 nm. 
 
3.11. In vivo xenograft tumor growth 
Xenografted tumors were obtained by subcutaneous injection of 5x10
6
 
human KS-Imm cells/mouse, and mixed with liquid matrigel into the 
flanks of seven-week-old male nude nu/nu (CD-1) BR mice (Charles 
River Laboratories) as described previously (Albini et al., 2001; Albini 
et al., 1997). Tat s-Met peptide was injected with cells (300 µl final 
volume of 10 µM peptide corresponding to 34 mg/ml) and then every 
second day by peri-tumor injection, whereas control animals received 
vehicle alone. In another experiment, the Antp-Met peptide (300 µl final 
volume of 10 µM peptide corresponding to 43 mg/ml) was injected after 
the tumors had become established. Animals were weighed and tumor 
growth monitored at regular intervals by measuring the two tumor 
diameters with a caliper. After the animals were killed, tumors were 
removed, weighed and processed for histological examination. All 
procedures were performed in adherence with the ECC Directive for 
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Care and Italian Laws on animal experimentation (Law by Decree 
116/92). 
 
3.12. Histological analysis 
Sections of 3 µM thickness were stained with hematoxylin– eosin for 
histological examination. For immunohistochemistry, slides were 
deparaffinized in xylene, rehydrated and antigens retrieved in EDTA 
(pH 8); thereafter, the sections were treated with 3% of hydrogen 
peroxide, incubated with rabbit polyclonal CD11b/c antibody (1:600) 
(ABR, Golden, CO, USA) and peroxidase-coupled anti-rabbit 
immunoglobulin secondary antibodies, followed by reaction with 3,30- 
diaminobenzidine (Dako REAL EnVision system, Peroxidase/ 
diaminobenzidineþ, Dako, Glostrup, Denmark) and finally 
counterstained with Mayer’s hematoxylin (Sigma). For 
immunofluorescence microscopy, primary antibodies against von-
Willibrand factor (rabbit anti-mouse, 1:100) (Millipore, Temecula, CA, 
USA) and Met (mouse anti-mouse, 1:100) (Santa Cruz Biotechnology 
Inc) were diluted in background reducing diluent (Dako) and applied for 
1 h at room temperature, after the incubation with blocking serum (3% 
goat serum). Fluorescent secondary antibodies Alexa Fluor goat anti-
rabbit 488 (1:50) (Invitrogen, Eugene, OR, USA) and goat anti-mouse 
555 (1:30) (Invitrogen) were diluted in PBS buffer and applied for 1 h at 
room temperature. Nuclei were labeled with Vectashield mounting 






3.13.  Statistical analyses 
Statistical analyses were performed using two-tailed t-tests for 
comparison of two data sets, one-way analysis of variance for multiple 
data sets and two-way analysis of variance for growth curves, using the 




4.1. Cell internalization of the Met docking site peptide 
The plasma membrane, which limits cell internalization of most proteins 
and peptides, can be crossed by cell-penetrating peptides, such as Tat 
and Antp, which can be used to deliver peptides into living cells. We 
verified efficient peptide internalization by incubating 5-(and-6)-
carboxyfluorescein (FAM)-conjugated Tat-Met peptide (10 µM) with 
human umbilical vein endothelial cells (HUVEC) and monitoring 
fluorescence with flow cytofluorimetry. Peptide uptake was time 
dependent, with more than 50% of the cells being fluorescent after as 
























Figure 7: The Tat-Met peptide enters into HUVECs. Tat-Met was conjugated 
at the N-terminus with FAM. HUVECs (1x10
5
) were incubated for different 
periods of time with 10 µM peptide, washed twice and analyzed by 
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fluorescence-activated cell sorting. Labelled Met peptide devoid of the cell-
penetrating peptide motif and untreated cells (CTRL) were used as controls. 
Representative dot plots of peptide internalization percentage are shown. 
 
A FAM-conjugated Met peptide lacking the Tat cell-penetrating peptide 
motif did not cross the cell membrane even after extensive incubation, 
showing levels of fluorescence similar to those of control untreated 
HUVEC. 
The internalisation of labelled Tat-Met peptide was visualized even by 












Figure 8: Subconfluent monolayers of HUVE cells were incubated for 2 hours 
with 10 µM labelled Tat-Met peptide, washed and analysed by confocal 
microscopy. Confocal images were obtained by a Leica TCS SP confocal scan. 
After excitation at 488 nm, green fluorescent images of the internalised peptide 
were analyzed by Leica software. (Representative picture, magnification 63X). 
 
4.2. Met docking site peptides inhibit HUVEC proliferation 
The cell penetrating Antp-Met and Tat-Met peptides were tested for 
their ability to interfere with HGF-induced proliferation of HUVEC and 
compared with PHA-665752. Significant inhibition of cell growth in 
MTT assays was observed at doses of 10 µM Antp-Met already after 24 
hours of treatment (Figure 9A). Higher concentrations of the Antp-Met 
completely abolished cell proliferation. Tat-Met and Tat s-Met 
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(containing a shorter Tat peptide), used at 10 µM concentrations, 
showed a significant reduction of cell proliferation only after 48 h 
(Figure 9B, C). At higher concentrations (20 µM and 50 µM) they 
displayed a cytostatic activity starting from 24 hours of incubation. 
Lower concentrations of peptides (1 µM) did not have any effect even in 
longer treatments.  
In contrast, we observed a marked inhibitory effect starting, from the 24 
hour time point when we exposed endothelial cells to micromolar 
concentrations (5 µM and 10 µM) of PHA-665752 (Figure 9D). Lower 
PHA-665752 concentrations did not exert any significant reduction on 
proliferation with respect to the control.  
These data show that the internalized Met peptides inhibited cell 
proliferation, the Antp-coupled Met peptide appears to have a stronger 
inhibitory activity, whereas PHA-665752 required relatively high 






















Figure 9: The Met docking site peptide inhibits HUVEC proliferation. Cell 
proliferation was evaluated at fixed times after the addition of HGF (50 ng/ml) 
± Antp-Met (a), Tat-Met (b), Tat s-Met (c) or PHA-665752 (d) at different 
concentrations in 2% FBS-containing medium. The inhibitory effect of Antp-
Met (10 µM) was already significant after 24 h, whereas the inhibitory effect of 
Tat-Met or Tat s-Met peptides were significant only after 48 h and when 20 µM 
concentrations were used. PHA-665752 showed an inhibitory marked 
reduction from 24 h at µM concentrations, whereas lower concentrations did 
not exert a significant reduction of proliferation with respect to the control. 
Means ± s.e.m. are shown (p<0.05). 
 
4.3. Met docking site peptides do not exert toxicity or induce 
apoptosis in endothelial cells 
The possibility that the Met inhibitors employed could exert toxicity or 
induce endothelial cell apoptosis, was evaluated by cytofluorimetric 
analysis. After only two hours of treatment of endothelial cells in the 
presence of HGF with 250 nM PHA-665752, approximately 60% of the 
cells (Figure 10A) were already undergoing apoptosis (both annexin V 



























Figure 10: Met docking site peptides do not induce toxicity or apoptosis in 
endothelial cells. In the apoptosis assay, HUVECs were plated onto six-well 
plates and were treated with eithethe Antp-Met peptide (10 µM), Tat-Met 
peptide (10 µM) or Tat s-Met peptide (10 µM) or with increasing 
concentrations of PHA-665752 (250 and 500 nM, and 1 and 5 µM). Vehicle 
(dimethyl sulfoxide) and growth medium alone were used as controls, and 
HGF 50 ng/ml (panel a) or 10% FBS (panel b) were added to the growth 
medium. After 2 h, cells were recovered, washed and stained with two markers, 
Annexin V and 7-amino-actinomycin D, used to detect viable, dead or cells 
undergoing apoptosis. After only 2 h, 250 nM PHA-665752 induced late 
apoptosis in about 60% of endothelial cells in HGF-containing media (a); on 
the contrary, 10 µM peptides showed an high percentage of viable endothelial 
cells (about 95% of the population; a). The toxicity of PHA-665752 was 
marked both in the presence of HGF (a) or FBS (b). The experiment was 
performed three times and each condition was in triplicate. 
 
In contrast, cells treated with the peptides even the highest 
concentrations showed a high percentage (about 95%) of viable 
endothelial cells and no apoptosis (Figure 10A). The toxicity of PHA-
665752 was observed even in the presence of serum (FBS) with clear 
dose dependent effects (Figure 10B). These data suggest that the growth 
inhibition exerted by of PHA-665752 may be due to cytotoxicity and 
apoptosis. 
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4.4. Met docking site peptide specifically inhibits HGF-dependent 
HUVEC migration and invasion 
Endothelial cells must cross basement membranes to form new blood 
vessels during angiogenesis; we investigated whether the peptides could 
affect HGF-dependent HUVEC motility and invasion. Under the effect 
of HGF (50 ng/ml), the number of the migrated cells in a Boyden 
chamber assay doubled, a non-cytotoxic dose of 10 µM peptides 
abrogated this migration (Figure 11A; *p<0.05). No significant 
differences in migration inhibitory activity were found among the 
different peptides. We observed equivalent inhibitory effects with PHA-
6657525 only in presence of the highest (cytotoxic) concentrations (5µ 
and 10 µM) (Figure 11B). The Met peptides did not inhibit VEGF-
dependent cell migration (Figure 11C), thus showing clear specificity.  
In an invasion assay performed in Boyden chambers with filters 
precoated with a reconstituted basement membrane (matrigel), treatment 
with Tat-Met or Tat s-Met significantly reduced the HGF-induced 
invasion (Figure 11D). Tat s-Met displayed a higher inhibitory activity 
than Tat-Met (*p<0.05) and in both cases a dose-dependent effect was 



























Figure 11: The Met docking site peptide strongly inhibits HGF-dependent 
HUVEC migration and invasion. In the migration assay, HUVECs were seeded 
into the upper compartment of Boyden chambers in the presence or absence of 
Antp-, Tat- and Tat s-Met peptides or PHA-665752, whereas chemoattractants 
(50 ng/ml HGF (a) or 10 ng/ml VEGF (c)) were placed in the lower 
compartment. After 6 h incubation, cells in the upper side of the filter were 
removed, and cells that migrated to the lower surface were fixed, stained and 
counted. Serum-free medium (SFM) was used as negative control. Met 
mimicking cell-penetrating peptides inhibited HUVEC migration induced by 
HGF, but not that induced by VEGF. The inhibitor PHA-665752 showed the 
same inhibitory effect of peptides on HGF-dependent migration only at the 
highest concentrations (5 and 10 µM). The invasion assay was performed 
similarly, except that the filter separating the two compartments was pre-
coated with matrigel and incubation was for 18 h. Tat- and Tat s-Met peptides 
inhibited HGF-induced matrigel invasion in dose-dependent manner (d). All 
experiments were performed in triplicate and repeated three times. Means ± 
s.e.m. are shown (*p<0.05). 
 
4.5. The Met docking site peptide inhibits endothelial 
morphogenesis in vitro  
HUVECs can organize into capillary-like structures when cultured on a 
thick matrigel layer in presence of angiogenic factors. The Met peptides 
interfered with HGF-induced HUVEC morphogenesis with the same 
efficacy shown in inhibiting cell proliferation (Figure 12). Antp-Met was 
effective at 10 µM (Figure 12 E), while Tat-Met and Tat s-Met were 
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effective at 20 µM (Figure 12 G and I). Antp-Met did not affect FBS-
dependent network formation, showing specificity of the inhibitory 
effect (Figure 12 K).  
PHA-665752 interfered with HGF-dependent tube formation to a similar 






























Figure 12: The Met docking site peptide inhibits morphogenesis in vitro. 
HUVECs spontaneously organize in capillary-like networks after 6 h 
incubation at 37 °C as shown. Figure 3 C-E: effect of Antp-Met peptide 
on HGF-dependent tube formation. The peptide dose-dependently 
inhibited growth and differentiation of HUVE cells, starting at 
concentrations of 5 µM; inhibition was essentially complete at 10 µM, in 
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the presence of HGF (magnification 5X). Figure 3 F-I: effect of Tat-Met 
peptides on HGF-dependent tube formation. The peptides showed an 
inhibitory effect at the highest concentration of 20 µM (magnification 
5X). Figure 3 J-K: effect of Antp-Met peptide on FBS-dependent tube 
formation. The peptide did not inhibit serum-dependent growth and 
differentiation of HUVE cells (magnification 10X). Figure 3 L-S: effect 
of PHA 665752 on HGF-dependent tube formation. PHA-665752 
interfered with HGF-dependent tube formation only at cytotoxic 
micromolar concentrations (magnification 5X). 
 
4.6. The Met docking site peptide inhibits HGF-dependent 
downstream signalling 
The different biological responses triggered by HGF and mediated by 
Met depend on efficient downstream signal transduction, which in turn 
depends on receptor tyrosine phosphorylation. The binding of HGF 
leads to the activation of the two major signalling pathways, the ERK1/2 
and the phosphoinositide 3-kinase (Birchmeier et al., 2003; Boccaccio 
and Comoglio, 2006).  We tested whether Antp-Met impaired Met 
receptor phosphorylation in the catalytic loop and in the docking site. 
While phosphorylation on tyrosines 1234-1235 localized in catalytic 
loop was not affected, phosphorylation on tyrosine 1349, localized in C-
terminal docking site showed a 70% reduction when Antp-Met was 
added to cells 2 hours before stimulation with 10 ng/ml HGF (Figure 
12A). Phosphorylation of ERK1/2, which is mainly involved in 
transducing proliferation and motility responses (Birchmeier et al., 
2003; Prat et al., 1998), was also impaired by the Antp-Met peptide 
(Figure 13A). Taken together, these data show that Met-derived peptides 
inhibit the phosphorylation of the tyrosines located in this motif, and 
block activation of the downstream signalling, but do not affect 















Figure 13: The Met docking site peptide inhibits the HGF-dependent 
downstream signalling. Quiescent HUVECs were pretreated or not for 2 h with 
Antp-Met before stimulation with 10 ng/ ml HGF for 15 min, and then lysed 
and processed for Western blot analysis. Blots were probed with anti-phospho 
Met (tyrosine 1349), anti-phospho Met (tyrosines 1234–1235), anti-phospho 
ERK1/2, anti-Met and anti-a-tubulin. Antp-Met inhibited the phosphorylation 
of tyrosine 1349, but not of tyrosines 1234–1235. Besides, the phosphorylation 
of ERK1/2 was impaired by Antp-Met (a).(b) Human and murine endothelial 
cell lines, HUVEC and 1G11, respectively, express Met receptor protein. 
 
4.7. Met docking site peptide inhibits in vivo angiogenesis 
We assessed the effect of the Met peptides on in vivo angiogenesis using 
a rapid and quantitative matrigel sponge assay. A cocktail of HGF (50 
ng/ml) and heparin (50U/ml) promoted a hemorrhagic vascularization of 
the matrigel sponge clearly detectable at 4 days post-implantation 
(Figure 14A). Addition of the different Met derived peptides (10 µM) 
significantly inhibited the HGF-induced angiogenic response, as 
detected by visual inspection of the pellets and measured in a 
hemoglobin quantification assay (***p<0.001) (Figure 14B). The 
inhibition was specific, as shown by the lack of effect on the angiogenic 
response of an Antp-Met peptide whose sequence had been scrambled 
(Figure 14B). Hematoxylin-eosin stained sections of pellets showed that 
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the extensive vascularized areas in mice treated with HGF and heparin 
were substantially reduced in mice treated with the Met peptides (10µM) 
(Figure 14C (a, b, c)).   
Immunohistochemistry showed that CD11b/c positive cells were readily 
detected within pellets containing HGF and heparin, indicating the 
presence of an inflammatory response; this infiltrate was significantly 
































Figure 14: The Met docking site peptide inhibits in vivo angiogenesis. A 
cocktail of HGF (50 ng/ml) and heparin (50 U/ml) promoted a hemorrhagic 
vascularization of the matrigel sponge clearly detectable at 4 days post-
implantation. HGF-induced vascularization of the subcutaneously injected 
matrigel implants was significantly inhibited by the addition of micromolar 
concentration of Met peptides, as detectable at visual inspection (A) and 
quantified by measuring hemoglobin (Hb) content of the pellets (B) 
(***p<0.001). Representative histological specimens that were stained with 
hematoxylin and eosin show extensive necrotic areas (C (a, b and c)). 
CD11b/c immunohistochemistry on adjacent sections show 
abrogation/impairment of cellular infiltrates in the pellets treated with the 
peptides (C(a’, b’ and c’)) (40X magnification). 
 
4.8. Met docking site peptide inhibits the growth and 
vascularization of Kaposi's sarcomas in nude mice  
We next examined whether the peptides were able effect growth and 
vascularization of tumors in vivo. KS-Imm Kaposi’s Sarcoma cells were 
injected in liquid matrigel with or without Tat s-Met (10 µM), followed 
by treatment with peptides s.c. every second day until termination of the 
experiment. Treatment with the Tat s-Met peptide clearly inhibited 
tumor growth (Figure 15A). H&E staining of sections of tumors showed 
extensive areas of vascularization in control tumors, while extensive 
necrotic areas and strongly reduced vascularization were found in 
tumors of animals receiving peptides (Figure 15B (a, b)). 
Immunohistochemical staining indicated that in peptide treated tumors 
CD11b/c positive inflammatory cells were significantly reduced (Figure 
15B (a’, b’)). To confirm the reduction of vascularization in tumors 
treated with peptide, we performed an immunofluorescence analysis for 
the endothelial marker von Willebrand (Figure 15C (b, b’)) and we 
observed an higher number of von Willebrand positive cells in control 
tumors (Figure 15C (b)) than in tumors treated with Tat s-Met (Figure 
15C (b’)). We observed co-localization of the Met receptor and the von 
Willibrand endothelial marker in the tumors (Figure 15C (c, c’)), 
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suggesting that murine tumor endothelial cells express Met. This was 
consistent with the presence of Met (Figure 13B) in the 1G11 murine 
lung microvascular endothelial cell line (Dong et al., 1997). 
In another set of experiments, Antp-Met, or a scrambled peptide (both at 
10 µM), were injected in the peritumor area every second day after the 
tumor was established. Again, the peptide significantly inhibited tumor 
growth, while the scrambled peptide had no effect on tumor growth 
(Figure 15D). The central necrotic areas (Figure 15E (a, b)) and the 
strong inflammatory infiltrate (Figure 15E (a’, b’)) again were strongly 
reduced in presence of the Met peptide as compared to controls 
receiving either vehicle alone or scrambled peptide. These data indicate 
that the Met peptides, while not toxic for healthy endothelial cells, 



















Figure 15: The Met docking site peptide impairs the growth and 
vascularization of established Kaposi’s sarcomas in nude mice. Mice with 
xenografted Kaposi’s sarcoma tumors (either established (D, E) or not (A, B)) 
were injected peri-tumorally with equimolar concentrations of either Antp-Met, 
Tat s-Met or Antp-scrambled (150 ml final volume of a 10 µM solution) or 
vehicle alone (control) every second day, as indicated. (A) Tumor growth 
analysis showed a significant inhibition of tumor growth by Tat s-Met. (B) 
Hematoxylin and eosin staining of the Kaposi’s sarcoma xenografts grown in 
mice treated with Tat s-Met (b) showed extensive necrotic areas, when 
compared with tumors from control mice receiving only vehicle (a). 
Immunostaining of adjacent sections with CD11b/c, a marker of inflammatory 
infiltrates, showed that Tat s-Met treatment strongl inhibited the inflammation 
associated with the tumor (b’), relative to treatment with vehicle alone 
(control) (a’). (C) Immunofluorescence staining of Kaposi’s sarcoma xenograft 
sections for the endothelial marker von Willibrand (b and b’) and Met receptor 
(c and c’). The number of positive von Willibrand cells in control tumors (b) 
was much higher than that in xenografts treated with Tat-s (b’). The effect of 
the peptide on vascularization was Met-related, as showed by the 
colocalization of the Met receptor with the von Willibrand endothelial cell 




significantly inhibit tumor growth in vivo. In contrast, a scrambled control 
peptide had no effect on tumor growth, showing the role of specific Met 
inhibition. (E) Hematoxylin and eosin staining of the Kaposi’s sarcoma 
xenografts grown in mice treated with Antp-Met (b) showed extensive necrotic 
areas, as compared with tumors from control mice receiving only vehicle (a). 
CD11b/c immunostaining of adjacent sections also showed a strong Antp-Met 
inhibition of tumorassociated inflammation (b’) as compared with controls (a’) 
(40X magnification). 
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5. Discussion and conclusions 
 
Angiogenesis is associated with several pathologies, including chronic 
inflammation and arthritis, atherosclerosis, macular degeneration and 
cancer (Carmeliet and Jain, 2000); therapeutic strategies have envisioned 
angiogenesis as promising target (Carmeliet and Jain, 2000; Ferrara, 
2004; Folkman, 1985; Goh et al., 2007). HGF and its receptor Met are 
able to stimulate endothelial cell migration, proliferation and 
organization into capillary-like tubes and angiogenesis (Bussolino et al., 
1992; Grant et al., 1993; Silvagno et al., 1995). HGF can induce pro-
angiogenic cytokine expression, directly activating angiogenic pathways 
(Dong et al., 2001; Sengupta et al., 2003) or down-regulating the 
expression of angiogenic inhibitors (Zhang et al., 2003) and promoting 
lymphangiogenesis (Cao et al., 2006). The HGF/Met axis has been 
proposed as a target for anti-angiogenic therapy (You and McDonald, 
2008).  
Structural and functional integrity of endothelial cells is a fundamental 
for vessel homeostasis and function. Alterations of endothelium are 
associated with increased risk for several diseases, including 
cardiovascular diseases and adverse events. Agents affecting endothelial 
integrity inducing apoptosis or direct toxicity, are likely induce vascular 
dysfunction. Several small molecule drugs targeting Met and other 
kinases show toxicity, thus biological molecules could be used to 
obtained higher levels of specificity and lower toxicity in Met inhibition.  
Here we describe the anti-angiogenic properties of synthetic cell-
permeable peptides binding selectively the C-terminal tail of Met in the 
absence of cytotoxicity or apoptosis induction. These peptides inhibit 
HGF-induced proliferation, migration, invasiveness, and capillary-like 
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network formation in endothelial cells in vitro. Comparison of our 
peptides with the ATP-competitive inhibitor PHA-665752, showed that 
similar inhibitory effects were obtained only at high concentrations of 
PHA-665752 associated with apoptosis and toxicity. The ability of these 
peptides to interfere with pathological responses with no cytotoxic 
effects would be of clinical relevance to minimize the additive toxicity 
phenomena due to the administration of multiple inhibitor drugs.   
The Met docking site peptides were active in vivo, blocking HGF-
induced angiogenesis and restraining growth and vascularization of 
xenografted tumors; this is the first report of the in vivo inhibiting 
activity of a Met-specific cell penetrating peptide. Homozygous genetic 
deletion of either Met or HGF is lethal in utero due to defects in 
placental development (Bladt et al., 1995; Schmidt et al., 1995; Uehara 
et al., 1995). However, the Met-/- mice did not show an endothelial 
phenotype (Bladt et al., 1995) and the morphological appearance of 
endothelium in HGF-/- embryos was not altered (Uehara et al., 1995). 
These data suggest that the Met/HGF axis may play a major role in 
pathological but not in physiological angiogenesis, as proposed for other 
angiogenic factors such as PlGF (Fischer et al., 2008). This would be 
consistent with of Met in endothelial cells (Figure 13B), the co-
expression with endothelial marker in vivo (Figure 15B) and the lack of 
toxicity in vitro and in vivo.   
Biochemically, the peptides strongly impaired HGF-dependent 
activation of the Ras-MAPK ERK1/2 transduction pathway (Birchmeier 
et al., 2003; Ponzetto et al., 1994), consistent with previous in vitro 
studies in epithelial cells (Bardelli et al., 1999). The Met-specific 
peptides was delivered into cells by fusion with the internalization 
sequences from the Antennapedia homeodomain 3 or the HIV-Tat basic 
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domain, which proved to act efficiently as transporters across 
membranes (Deshayes et al., 2005; Foged and Nielsen, 2008; Gupta et 
al., 2005; Morris et al., 2008; Stewart et al., 2008). A similar peptide 
fused to the Tat internalizing sequence enhanced in vitro 
chemosensitiviy of glioma cells to a cisplatinum derivative (Lou et al., 
2009). The three peptides containing the Met docking site coupled to 
different internalizing sequences displayed only small differences in 
their inhibitory efficiency in vitro and in vivo. The three peptides 
displayed clear specificity for Met receptor, they did not impair VEGF- 
or FBS-induced effects on endothelial cells in vitro, and a scrambled 
peptide was ineffective in vivo.  
The Met-specific peptide inhibited the phosphorylation of Y1349, which 
binds the p85 regulatory subunit of PI3-K (Bardelli et al., 1999; Graziani 
et al., 1991; Lou et al., 2009; Ponzetto et al., 1994), mainly involved in 
transducing HGF-dependent motogenic and anti-apoptotic responses 
(Deregibus et al., 2003; Giordano et al., 2000; Khwaja et al., 1998; 
Ponzetto et al., 1993). Phosphorylation of the MAPK ERK1/2, whose 
activation is required for the proliferative and invasive responses 
(Bardelli et al., 2005; Birchmeier et al., 2003; Ponzetto et al., 1994; Prat 
et al., 1998), was impaired. While strongly interfering with the 
activation of the tyrosines located in the docking site, the peptide had no 
effect on phosphorylation of Y1234-1235, localized in the activation 
loop, as it appears to compete with substrate access to the catalytic 
pocket (Bardelli et al., 1999).  
Current clinical approaches to targeting angiogenesis have focused on 
blocking VEGF signalling by either anti-VEGF antibodies or 
multitargeted receptor tyrosine kinase inhibitors (Carmeliet and Jain, 
2000; Ferrara, 2004; Folkman, 1985; Goh et al., 2007; Loges et al., 
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2009). Current clinical experience has revealed that VEGF-targeted 
therapy prolongs overall survival of cancer patients by only months, and 
experimental models have recently shown that anti-VEGF treatment 
inhibits primary tumor growth, but may promote invasiveness and 
metastasis (Ebos et al., 2009; Paez-Ribes et al., 2009; Pennacchietti et 
al., 2003). In addition, the potential side effects that occur in the short-
term or long-term use of the anti-VEGF treatment are becoming 
apparent. Some of these side effects include gastrointestinal 
perforations, impaired wound healing, bleeding, hypertension, 
proteinuria, and thrombosis (Chen and Cleck, 2009; Higa and Abraham, 
2009; Zangari et al., 2009). Many of the side effects are actually due to 
the direct effects of the drugs; cardiovascular complications are believed 
to be caused by the direct effects of angiogenesis inhibitors on the non 
tumor-associated ECs (Zangari et al., 2009). It has also been 
demonstrated that most tumors develop mechanisms of resistance to 
anti-angiogenic treatment (Eikesdal and Kalluri, 2009) as a consequence 
of the long-term administration of anti-angiogenesis inhibitors. Because 
multiple signalling pathways are involved in angiogenesis, there is a 
signalling redundancy, and the block of a single pathway may not be 
highly effective and/or can lead to resistance when the tumor cells 
develop other angiogenesis mechanisms (Eikesdal and Kalluri, 2009).  
By targeting multiple pathways, resistance may be able to be overcome 
or delayed, making combination drug therapies important in the design 
of future clinical trials. The fact that Met is both a pro-angiogenic factor 
and an oncogene suggested that it may be an optimal target for anti-
cancer treatment, simultaneously inhibiting angiogenesis and 
oncogenesis (Michieli et al., 2004) and potentially complementing 
VEGF targeted anti-angiogenic therapy.  
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Our observations provide the novel result that Met-specific peptides 
mimicking the tail multifunctional docking site can block angiogenesis 
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